Date(s) - 12/03/2012
11:45 am - 12:35 pm
Harnessing RNA interference machinery endogenously present in mammalian cells through delivery of synthetic small interfering RNA (siRNA) has tremendous potential to be used clinically to reduce expression of disease-causing genes. My group and others have made significant strides toward provision of platforms that can enable translation of RNA interference into the clinical realm. This talk will focus on new technologies that have been developed in the Duvall lab for (1) scaffold-based, local delivery of siRNA for tissue regeneration applications (2) nanocarrier-based, systemic delivery of siRNA targeted through cell receptor-mediated and MMP-dependent, environmentally-activated mechanisms.